Creo Medical Group PLC (AIM:CREO) said trading so far this year has been strong, continuing the momentum seen in 2021.
“The solid progress made over the past year underpins the board's continued confidence in the group's opportunities in 2022 and beyond,” chairman Charles Spicer said in a statement issued ahead of today’s AGM.
The medical device company focused on surgical endoscopy saw its total sales in 2021 rise to £25.2mln from £9.4mln the year before.
READ: Creo Medical signs collaboration with NASDAQ-listed medtech Intuitive
Spicer said the commercialisation of the company’s endoscopy devices continues at pace.
“We anticipate that high vaccination rates in both Europe and the US will continue to lessen the impact of COVID-19 during the remainder of 2022, allowing clinicians to focus on the huge backlog of elective cases, increasing activity in our key areas of clinical focus - core GI and soft tissue ablation,” he added.